In addition, as microsatellite instability (MSI) is one biomarker for response to PD-L1 and CTLA-4 immunotherapies and good prognosis in colon cancer (28–31), we explored the frequency of MSI to predict the number of AA patients that could benefit from these immunotherapies that appear to be effective in CA colon cancer patients (28–31). The gene discussed is CTLA4; the disease is malignant colon neoplasm.